- 首頁
- 科研細(xì)胞
- 藥靶模型
-
診斷試劑
腫瘤早篩甲基化標(biāo)準(zhǔn)品
遺傳性基因標(biāo)準(zhǔn)品
優(yōu)生優(yōu)育標(biāo)準(zhǔn)品
HLA標(biāo)準(zhǔn)品
數(shù)字PCR
- 技術(shù)服務(wù)
- 新聞中心
- 資源中心
- 關(guān)于我們
- 聯(lián)系我們
藥靶模型
Drug Target Model
CBP73372
I. Introduction | |
Cell Line Name: | KRAS G12C-R68M/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+2ug/ml puromycin |
Mycoplasma Status: | Negative |
II. Background | |
KRAS, KRAS proto-oncogene, GTPase, is a member of the small GTPase superfamily and a key regulator of the MAPK, PI3K/AKT/mTOR pathways (PMID: 23622131). KRAS mutations are identified in a wide range of cancers (PMID: 28666118). |
|
III. Representative Data | |
1.Sanger of KRAS G12C-R68M/BaF3
Figure 1. KRAS(NM_033360.4):c.34G>T p.G12C
Figure 2. KRAS(NM_004985.5): c.203G>T p.R68M |
|
2. Anti-proliferation assay
Figure 3. CTG Proliferation Assay of KRAS G12C/R68M BaF3 Cells (C2). |
相關(guān)產(chǎn)品推薦